Aditxt reiterates Sept 2025 close target for Evofem deal; Evofem had $19.5M revenue, first ex-US deal signed

Aditxt, Inc.

Acquisition of Evofem targeted to close by September 2025; conditions include resolving senior creditor and Evofem shareholder vote.
Evofem generated $19.5M net revenue last year; has two FDA-approved products (Phexxi, Solosec) and signed first ex-US deal with Pharma 1 in Middle East.
New manufacturer Lee Pharma committed to lowering Evofem's COGS by over 50% to mitigate tariff volatility and support European expansion.
Pearsanta's endometriosis/ovarian cancer diagnostic platform expected near revenue in Q4 2025; Adimune autoimmune program targets regulatory filing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.